Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
ImmunoGen, Inc.
Type
Public
Traded as NASDAQ: IMGN
Industry Biopharmaceuticals
Founded 1981
Headquarters Waltham, Massachusetts, United States
Number of employees
280
Website www.immunogen.com

ImmunoGen, Inc. (NASDAQ: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.

Currently approved ADCs with ImmunoGen technology employ one of the company's maytansinoid cell-killing agents, either DM1 or DM4, or one of the company's DNA-acting IGN payloads.

ImmunoGen also developed isatuximab, a monoclonal antibody without linkage to a toxin.

ImmunoGen uses its ADC technology to develop its own product candidates. Products currently in clinical-stage development include:

The company also selectively outlicenses limited use of its technology to other companies. Companies licensing ImmunoGen's technology include Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi, and Takeda. Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and launched in a number of countries, including the US, where it is marketed by Genentech, a member of the Roche Group. In October 2015, the company disclosed that Kadcyla had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2-positive advanced gastric cancer.


Investment goal date:
Dividends reinvested
ImmunoGen, Inc. IMGN report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-29
--
--
Q4 2017
2018-02-08
--
--
Q4 2017
2018-02-05
--
--
Q3 2017
2017-11-03
--
--
Q3 2017
2017-11-03
-0.6100
-0.6100
Q2 2017
2017-07-28
-0.1000
-0.1000
Q1 2017
2017-05-05
-0.2000
-0.2000
Q4 2016
2016-08-04
-0.5100
-0.5300
Q3 2016
2016-04-29
-0.3700
-0.3700
Q2 2016
2016-01-29
-0.3800
-0.3800
Q1 2016
2015-10-27
-0.3900
-0.3900
Q4 2015
2015-07-31
-0.3500
-0.3500
Q3 2015
2015-04-24
-0.2500
-0.2500
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BAKER BROS. ADVISORS LP
3015353
BlackRock Fund Advisors
2514221
BlackRock Inc.
5368099
BlackRock Institutional Trust Company, N.A.
2177724
Clearbridge Investments, LLC
14428856
DEUTSCHE BANK AG\
1765021
ORBIMED ADVISORS LLC
6095647
PANAGORA ASSET MANAGEMENT INC
1471763
PINNACLE ASSOCIATES LTD
1589959
PRIMECAP MANAGEMENT CO/CA/
3966000
Redmile Group, LLC
3984734
RENAISSANCE TECHNOLOGIES LLC
1477946
STATE STREET CORP
1598707
Vanguard Group, Inc
4110431
WELLS FARGO & CO/MN
1620279
Major Shareholders
Name Relationship
Total Shares
Holding stocks
JUNIUS DANIEL M
0.2300% (196700)
GLYC / IDXX / IMGN / VTAE /
BARROWS CRAIG
0.0500% (44050)
IMGN /
LAMBERT JOHN
0.1300% (110746)
IMGN /
MITCHELL DEAN J
0.0100% (10000)
IMGN / TBPH / XON /
PERRY GREGORY D
0.0200% (18337)
AEGR / IMGN / QLTI /
Williams Peter J.
0.0600% (50620)
IMGN /
Johnston David Brannon
0.2400% (201750)
AVEO / IMGN /
Morris Charles Q
0.0300% (27090)
IMGN /
Wingrove Theresa
0.1200% (102050)
IMGN /
Goldberg Mark Alan
0.0300% (23800)
GEVA / GLYC / IDRA / IMGN /
Enyedy Mark J
0.7000% (600100)
FATE / IMGN / KERX /
Gregory Richard J.
0.3200% (276481)
IMGN /
% ()